Anjaly Belur Curley MD, Presenter: Nothing to Disclose

Brendan Curley, Abstract Co-Author: Nothing to Disclose

Badreddine Bencherif MD, Abstract Co-Author: Nothing to Disclose

Danika Adria Hogan MD, Abstract Co-Author: Nothing to Disclose

1. Provide background information regarding NaF PET/CT imaging 2. Review indications for NaF PET/CT scan 3. Display interesting cases of patients undergoing NaF PET/CT in addition to other imaging, such as nuclear medicine bone scans, MRI, F-18 FDG PET/CT, or skeletal radiographs, and to describe the additional benefits provided by NaF PET/CT 4. Discuss prognostic relevance of NaF PET/CT imaging 5. Discuss future of NaF PET/CT imaging

1. Basics of NaF PET/CT Imaging 2. Imaging Protocol 3. Indications: a. Initial treatment strategy (initial staging of newly diagnosed cancer or suspicion for skeletal metastasis in patients without pathologically proven disease) b. Restaging (suspected new skeletal metastasis or progression of known osseous metastasis) c. Monitoring treatment (following chemotherapy, radiation, or both) 4. Benefits of F-18 NaF Imaging: a. Comparison with other imaging, b. Increase sensitivity &specificity compared to bone scans, anatomic correlation with CT, c. Faster, convenient, radiopharmaceutical readily available 5. Case review highlighting utility in clinical practice: several cases of patients with NaF PET/CT & other imaging at initial stage, restaging, and post-treatment stage 6. Limitations: a. Radiation exposure, cost & reimbursement, ordering clinician's knowledge of indications of study  

http://abstract.rsna.org/uploads/2014/14004628/14004628_n3r6.pdf

Curley, A, Curley, B, Bencherif, B, Hogan, D, The Utility of F-18 Sodium Fluoride PET/CT Imaging: Interesting Case Review.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14004628.html